In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc., with a price target of $36.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Judah Frommer’s rating is based on the promising developments in Bicara Therapeutics’ ongoing clinical trials, particularly the FORTIFI-HN01 study. The study involves ficerafusp alfa combined with pembrolizumab in HPV-negative head and neck squamous cell carcinoma, showing potential for improved outcomes compared to standard treatments.
Frommer also highlights the anticipated data from various dosing regimens in the Phase 1b trials, which could further inform the optimal dosing strategy for future phases. Additionally, the company’s financial stability, with a cash runway extending into the first half of 2029, supports the Buy rating by providing a solid foundation for continued research and development efforts.
According to TipRanks, Frommer is an analyst with an average return of -7.3% and a 42.45% success rate. Frommer covers the Healthcare sector, focusing on stocks such as Galapagos, RegenXBio, and PTC Therapeutics.